Hormonal
Baseline gut microbiome composition predicts the efficacy of semaglutide and empagliflozin in reducing HbA1c, whereas the drugs themselves do not significantly alter microbial diversity or composition.
If you are starting semaglutide or empagliflozin for Type 2 Diabetes, your current gut bacteria might predict how much your blood sugar (HbA1c) will drop. The drugs themselves don't seem to drastically change your gut diversity, but knowing your baseline microbiome could help personalize your treatment. This is still early research, so discuss testing options with your doctor.
Our findings suggest that semaglutide and empagliflozin impact the gut microbial community during treatment. In addition, the baseline gut microbiome can predict semaglutide treatment effects.
Why this rating
Small sample size (n=20), preprint status, and nominal significance after FDR correction limit the robustness.
Source
Fecal microbiome predicts treatment response after the initiation of semaglutide or empagliflozin uptake
Annabel Klemets et al. · Scientific Reports · 2026
DOI 10.1038/s41598-026-36318-3
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →